608 related articles for article (PubMed ID: 21081242)
1. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
[TBL] [Abstract][Full Text] [Related]
2. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
Bo S; Ciccone G; Rosato R; Villois P; Appendino G; Ghigo E; Grassi G
Diabetes Obes Metab; 2012 Jan; 14(1):23-9. PubMed ID: 21812892
[TBL] [Abstract][Full Text] [Related]
3. Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting.
Geraldine N; Marc A; Carla T; Chantal M; Stefaan B; Welcome W; Frank B
Diabetes Res Clin Pract; 2012 Aug; 97(2):331-6. PubMed ID: 22386769
[TBL] [Abstract][Full Text] [Related]
4. Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN).
Schiel R; Müller UA; Braun A; Stein G; Kath R
Eur J Med Res; 2005 Aug; 10(8):339-44. PubMed ID: 16131475
[TBL] [Abstract][Full Text] [Related]
5. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
Gulliford M; Latinovic R
Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
[TBL] [Abstract][Full Text] [Related]
6. Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus.
Bruno G; Merletti F; Boffetta P; Cavallo-Perin P; Bargero G; Gallone G; Pagano G
Diabetologia; 1999 Mar; 42(3):297-301. PubMed ID: 10096781
[TBL] [Abstract][Full Text] [Related]
7. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.
Mancini T; Mazziotti G; Doga M; Carpinteri R; Simetovic N; Vescovi PP; Giustina A
Bone; 2009 Oct; 45(4):784-8. PubMed ID: 19527806
[TBL] [Abstract][Full Text] [Related]
8. [Prevalence and pharmacotherapy of diabetes mellitus in primary care].
Lehnert H; Wittchen HU; Pittrow D; Bramlage P; Kirch W; Böhler S; Höfler M; Ritz E
Dtsch Med Wochenschr; 2005 Feb; 130(7):323-8. PubMed ID: 15712019
[TBL] [Abstract][Full Text] [Related]
9. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
McFarland MS; Cripps R
Pharmacotherapy; 2010 Nov; 30(11):1159-78. PubMed ID: 20973689
[TBL] [Abstract][Full Text] [Related]
10. Sulphonylureas and cancer: a case-control study.
Monami M; Lamanna C; Balzi D; Marchionni N; Mannucci E
Acta Diabetol; 2009 Dec; 46(4):279-84. PubMed ID: 19082520
[TBL] [Abstract][Full Text] [Related]
11. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].
Fabian W; Majkowska L; Stefański A; Moleda P
Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234
[TBL] [Abstract][Full Text] [Related]
12. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Schramm TK; Gislason GH; Vaag A; Rasmussen JN; Folke F; Hansen ML; Fosbøl EL; Køber L; Norgaard ML; Madsen M; Hansen PR; Torp-Pedersen C
Eur Heart J; 2011 Aug; 32(15):1900-8. PubMed ID: 21471135
[TBL] [Abstract][Full Text] [Related]
13. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
14. The joint effects of different types of glucose-lowering treatment and duration of diabetes on total and cardiovascular mortality among subjects with type 2 diabetes.
Khalangot M; Tronko M; Kravchenko V; Kulchinska J; Hu G
Diabetes Res Clin Pract; 2008 Oct; 82(1):139-47. PubMed ID: 18703252
[TBL] [Abstract][Full Text] [Related]
15. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
[TBL] [Abstract][Full Text] [Related]
16. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
17. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006.
Casscells SW; Granger E; Swedorske J; Goldhammer R; Shaheen M; Dorris J; Hong A; Wiktor M
Am J Ther; 2008; 15(3):198-205. PubMed ID: 18496256
[TBL] [Abstract][Full Text] [Related]
18. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort.
Dehal AN; Newton CC; Jacobs EJ; Patel AV; Gapstur SM; Campbell PT
J Clin Oncol; 2012 Jan; 30(1):53-9. PubMed ID: 22124092
[TBL] [Abstract][Full Text] [Related]
19. Cancer risk in diabetic patients treated with insulin glargine?
Prescrire Int; 2010 Aug; 19(108):162-3. PubMed ID: 20939447
[TBL] [Abstract][Full Text] [Related]
20. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
